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What proposals can we formulate 
to meet these requests? First, the 
Global Burden of Disease (GBD) has 
repeatedly highlighted the growing 
importance of NCDs.2 There is no 
further need to demonstrate the 
relevance of a public health approach. 
More over, as the debate initiated 
by Luke Allen and Andrea Feigl3,4 in 
The Lancet Global Health illustrates, 
socioenvironmental fac tors identi-
fied at the onset or aggravation 
of NCDs must be taken seriously to 
also fight communicable diseases 
more efficiently.5 Second, as these 
socioenvironmental causes, cofactors, 
and triggers of both NCDs and 
communicable diseases lie in living and 
working material conditions, money is 
needed to implement transdisciplinary 
research that would combine an 
in-depth clinical approach to the 
frequent diverse presentations of the 
diseases at stake, an epidemiological 
inquiry into the socioenvironmental 
sources of exposure to hazards, and 
social data collected through general 
population surveys, in association 
with thorough qualitative interviews, 
on people’s life trajectories, social 
habits, and daily practices. The results 
expected from such collaborations 
will not only provide a detailed 
description of environmental risk 
factors,6 but also a better know-
ledge of social determinants of 
health that are still unknown.7 Third, 
according to a cost-benefit approach, 
the resource breakdown should 
prioritise the situations that remain 
the most unreadable through the 
general pattern of the epidemiologic 
transition.8 In this respect, countries 
like South Africa would be on the 
front line, to understand the terrible 
combination of high prevalences of 
communicable diseases and grow-
ing prevalences of NCDs, and to 
provide preventive tools against 
socioenvironmental hazards in a 
context of large health inequalities. 
Finally, is it necessary to draw a “big 
political picture”?1 As Richard Horton 
reminds us, a lot has been done to 
These campaigns demonstrate the 
power of low cost, wide-reaching, 
inter sectoral, and innovative activities 
in informing and empowering the 
NCD movement.
The NCD tide is turning and we all 
have a part to play in driving positive 
change. Our organisations do not 
have all the answers, but we believe 
that engaging with young people 
and people living with NCDs through 
new and engaging media, as well 
as developing hard and soft skills to 
influence policy and hold governments 
accountable, are crucial steps. 
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the AIDS movement, YP-CDN, inspired 
by a need to apply a social justice and 
human rights frame to NCDs, has 
worked closely with traditional access 
to medicines activists and technical 
experts to add nine essential medicines 
for NCDs to the WHO Essential 
Medicines List.2 YP-CDN currently 
advocates, through its grassroots 
chapters in east Africa, for this global 
policy to be reflected at national levels.  
NCDFREE and the YP-CDN are 
preparing the next generation to lead 
on preventing and treating NCDs. 
Through NCDFREE’s bootcamps, 
hundreds of young people from 
varying personal and professional 
backgrounds in Australia, America, 
Canada, Denmark, Egypt, Germany, 
and the UK have gained awareness 
and advocacy skills to ignite systemic 
and sustainable change. NCDFREE 
is actively working toward a wider 
reach in all regions. YP-CDN’s NextGen 
Leaders programme, a partnership 
with RTI International, has trained 
more than 100 young people in east 
Africa since September, 2016, to 
advocate for local and national change 
on tangible country-specific NCD 
priorities set by young people, and to 
hold their governments accountable 
to their NCD commitments. While YP-
CDN’s chapter in Kenya is championing 
the cause of rheumatic heart disease, 
the chapter in Uganda is working with 
a civil society network on improving 
access to radiotherapy. 
“Be human. Be specific. Be vivid.”1 By 
communicating with our audi ences in a 
comprehensible manner through visual 
and engaging means—infographics, 
short films, social media, campaigns, 
and events—we can take our message 
to new and existing audiences, and 
most importantly, share the stories 
and voices of people living with NCDs. 
In 2013, NCDFREE’s #theface campaign 
collected personal NCD stories from 
around the world via social media. 
In 2016, the #feastofideas campaign 
again harnessed the power of social 
media to crowdsource 10 000 food 
system solutions from 56 countries. 
From (re-)framing NCDs 
to shaping public health 
policies on NCDs and 
communicable diseases
A senior adviser to the Global Fund 
taught Richard Horton (July 22, p 346)1 
some lessons that were drawn from the 
struggle against three communicable 
diseases—tuberculosis, malaria, and 
AIDS—that keep scourging global 
health. To raise funds to combat non-
communicable diseases (NCDs), one 
should “translate [one’s] evidence 
into clear and simple political (not 
technical) messages”, “articulate why 
[one] need[s] money—what exactly 
will [one] spend it on and what will be 
the results of that investment”, “break 
down [one’s] broad global demands 
into tangible country-specific needs”, 
and “connect [one’s] case to the big 
political picture—give it meaning”.
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community could do more to leverage 
global outbreak vernacular to mobilise 
additional resources for this neglected 
slow-motion disaster.6
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frame9 NCDs as a so-called public 
issue.10 To shift from framing to 
shaping public policies is the only way 
to make the public health targets of 
the Sustainable Development Goals 
effective and efficient, beyond slogans.
We declare no competing interests. Our contract 
grant sponsor is the European Research Council 
(ERC)/SILICOSIS project, Centre for European 
Studies, Sciences Po (Paris, France); contract grant 
number ERC-2011-ADG_20110406 (^Project ID: 
295817). We are joint first authors.
*Catherine Cavalin, Alain Lescoat
catherine.cavalin@sciencespo.fr
Centre for European Studies and Laboratory of 
Interdisciplinary Evaluation of Public Policies, 
Sciences Po, 75 337 Paris CEDEX 07, France (CC); 
Centre for Employment and Labour Studies, Cnam 
Centre, Noisy-le-Grand, France (CC); and UMR 
Inserm U1085, Research Institute in Health, 
Environment and Occupation/Institut de 
Recherche sur la Santé, l’Environnement et le 
Travail, and Department of Internal Medicine, 
University of Rennes 1, Rennes, France (AL)
1  Horton R. Offline: NCDs—why are we failing? 
Lancet 2017; 390: 346. 
2  GBD 2013 DALYs and HALE Collaborators. 
Global, regional, and national disability-
adjusted life years (DALYs) for 306 diseases 
and injuries and healthy life expectancy 
(HALE) for 188 countries, 1990–2013: 
quantifying the epidemiological transition. 
Lancet 2015; 386: 2145–91. 
3  Allen LN, Feigl AB. What’s in a name? A call 
to reframe non-communicable diseases. 
Lancet Glob Health 2017; 5: e129–30. 
4  Allen LN, Feigl AB. Reframing 
non-communicable diseases as socially 
transmitted conditions. Lancet Glob Health 
2017; 5: e644–46. 
5  Cavalin C, Lescoat A, Macchi O, Revest M, 
Rosental P-A, Jégo P. Socioenvironmental 
factors of communicable and 
non-communicable diseases. 
Lancet Glob Health 2017; 5: e487. 
6  Vineis P, Chadeau-Hyam M, Gmuender H, 
et al. The exposome in practice: design of the 
EXPOsOMICS project. Int J Hyg Environ Health 
2017; 220: 142–51. 
7  Laffey JG, Madotto F, Bellani G, et al. 
Geo-economic variations in epidemiology, 
patterns of care, and outcomes in patients 
with acute respiratory distress syndrome: 
insights from the LUNG SAFE prospective 
cohort study. Lancet Respir Med 2017; 
5: 627–38. 
8  Omran AR. The epidemiologic transition: 
a theory of the epidemiology of population 
change. Milbank Mem Fund Q 
1971; 49: 509–38. 
9  Goffman E. Frame analysis. an essay on the 
organization of experience. Boston: 
Northeastern University Press, 
1986: XVIII–586. 
10  Gusfield JR. The culture of public problems: 
drinking-driving and the symbolic order. 
Chicago: Chicago University Press, 
1981: XIV–263. 
You’re not speaking my 
language: reframing 
NCDs for politicians and 
policy makers
Richard Horton correctly identified 
inadequate framing as an important 
reason for why the world’s leading 
causes of death and disability—non-
communicable diseases (NCDs)—are 
not being seriously addressed by 
global leaders (July 22, p 346).1
The non-communicable misnomer 
wrong-foots the uninitiated and 
implicitly promotes individualistic 
above societal solutions.2 The most 
effective interventions are population-
level multisectoral policies that are 
unpopular with libertarians and much 
more challenging to introduce than 
individualistic, health-only initiatives.3 
There is some modelled evidence 
for the costs of action and inaction 
on NCDs,4 but it is written with little 
thought for the intended audience—
more technical document than 
policy brief. Again, there has been 
a move towards curating personal 
stories (eg, NCDs & me) but these 
efforts haven’t broken into the public 
consciousness yet. The average voter 
has no idea what an NCD is, nor do 
patients living with NCDs, nor the vast 
majority of health professionals. Why 
would politicians?
Changing the name might help.2 So 
would presenting evidence in policy 
makers’ own language with attention 
to returns on investment, trade-offs, 
and opportunity costs. Politicians 
need engaging narratives and ways 
of linking NCDs with priorities 
such as global warming, economic 
growth, and migration. President 
Trump’s recent budget proposal 
used a security framing that could 
work well for NCDs,5 especially since 
European leaders are being pushed to 
meet NATO spending commitments. 
A final, fruitful prism is pandemic 
preparedness, which is important 
to both President Trump and WHO 
Director-General Dr Tedros. The NCD 
For more on NCDs & me see 
http://apps.who.int/ncds-and-
me/
Concerns related to the 
nocebo effect
We read with interest the finding of 
Ajay Gupta and colleagues (June 24, 
p 2473)1 of an absence of attributable 
risk of muscle-related adverse events 
to statin therapy in the blinded 
randomised controlled phase by 
contrast with an excess risk in the non-
randomised, open-label extension 
phase in the same population. 
These results were attributed to 
the nocebo effect. We note that the 
overall proportion of participants 
reporting muscle-related adverse 
events was lower in the non-blinded, 
non-randomised phase than in the 
masked randomised phase. This might 
be explained by selective uptake or 
cessation of statins by participants in 
the follow-up phase, since 3364 (68%) 
of 4972 participants who had been 
randomly assigned to statin therapy 
made the choice to continue the drug 
in the open phase, whereas only 3045 
(62%) of 4927 participants who had 
been randomly assigned to placebo 
opted to take atorvostatin. It would 
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